Compositions and methods for targeted cytokine delivery
US-2024376169-A1 · Nov 14, 2024 · US
Compositions comprising IL-7 receptor ligands
US9266937B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9266937-B2 |
| Application number | US-201113992814-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 9, 2011 |
| Priority date | Dec 10, 2010 |
| Publication date | Feb 23, 2016 |
| Grant date | Feb 23, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated IL-7 mutant protein, derived from a wild type IL-7 protein having the amino acid sequence as set forth in SEQ ID NO:7, having an amino acid substitution at site T97, wherein the IL-7 mutant protein has reduced binding to an IL-7 receptor compared to binding of the wild type IL-7 protein to the IL-7 receptor. 2. The IL-7 mutant protein of claim 1 , wherein the binding of the IL-7 mutant protein to the IL-7 receptor causes an attenuated signal by the receptor. 3. The IL-7 mutant protein of claim 1 , wherein the T97 is substituted with valine. 4. A composition comprising the IL-7 mutant protein of claim 1 . 5. The composition of claim 4 , wherein the T97 of the IL-7 mutant protein is substituted with valine. 6. The composition of claim 4 , further comprising a pharmaceutically acceptable carrier. 7. An isolated nucleic acid encoding an IL-7 mutant protein derived from a wild type of IL-7 protein having the amino acid sequence as set forth in SEQ ID NO:7, having an amino acid substitution at site T97, wherein the IL-7 mutant protein has reduced binding to an IL-7 receptor compared to binding of the wild type IL-7 protein to the IL-7 receptor. 8. The isolated nucleic acid of claim 7 , comprising the nucleotide sequence of SEQ ID NO:3. 9. A vector comprising the nucleic acid of claim 7 or claim 8 . 10. An isolated host cell comprising the nucleic acid of claim 7 or claim 8 .
Assignees
Inventors
Classifications
Immunomodulators · CPC title
- C07K14/5418Primary
IL-7 · CPC title
- C07K14/54Primary
Interleukins [IL] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9266937B2 cover?
- Disclosed herein are novel proteins that have reduced binding to the interleukin-7 receptor, compositions containing such proteins, and methods of using the same.
- Who is the assignee on this patent?
- Khaled Annette, Univ Central Florida Res Found
- What technology area does this patent fall under?
- Primary CPC classification C07K14/5418. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).